CClinicalTrials.gg
CompletedNCT02812771Updated Nov 1, 2021Results posted

Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis

A Phase 4 interventional study of Efinaconazole in Onychomycosis, sponsored by Bausch Health Americas, Inc.. Completed at 10 sites in 2 countries. Open to participants aged 6 Years to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-01.

Sponsored by Bausch Health Americas, Inc. · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
6 Years to 16 Years
Sex
All
01

Study summary

Safety and Pharmacokinetics (PK) of a once daily topical application of efinaconazole in the treatment of pediatric subjects with mild to severe onychomycosis of the toenails.

Read the detailed description

This is an open label, single-arm study designed to evaluate the safety and PK of a once daily topical application of efinaconazole in the treatment of pediatric subjects with mild to severe onychomycosis of the toenails.

02

Conditions studied

  • Onychomycosis

Browse trials for

03

In context

Onychomycosis

147 studies on the registry are indexed under Onychomycosis; 13 are open to participants now.

This study's enrollment of 62 is above the median of 56 across 134 interventional studies indexed under Onychomycosis.

Browse Onychomycosis studies →

Lead sponsor

Bausch Health Americas, Inc. is the lead sponsor of 209 studies on the registry; 9 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 16 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Male or female subjects of any race, 6 to 16 years of age (inclusive). PK Subset: Male or female subjects of any race, 12 to 16 years of age (inclusive).
  • Verbal and written informed consent/assent obtained from the subject and/or their parent or legal guardian.
  • Good general health, as assessed by the investigator, based on the subject's medical history, physical examination, and safety laboratory tests.
  • Target great toenail for all subjects, and both great toenails for subjects in the PK subset, must have evidence of toenail growth, per subject's report that monthly clipping is needed.
  • Subjects and their parents/legal guardians are willing to comply with study instructions and return to the investigational center for all required visits (a visit schedule with the length of each visit will be provided to ensure that the subject can meet the requirements and have adequate transportation).

Key Exclusion Criteria:

  • Females who are pregnant, nursing an infant, or planning a pregnancy during the study period.
  • History of immunosuppression and/or clinical signs indicative of possible immunosuppression, as determined by the investigator, or known human immunodeficiency virus infection.
  • History of diabetes that is uncontrolled as determined by the investigator (diabetes that is controlled by diet or medication does not exclude a subject).
  • Presence of any toenail infection other than or in addition to dermatophytes, such as Scytalidium as determined by the investigator (candidal onychomycosis infection, concurrent with a positive dermatophyte culture, is acceptable).
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Efinaconazole

    Efinaconazole

    Drug: Efinaconazole

Interventions

  • DrugEfinaconazole

    Solution

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least One Adverse Event

    Time frame: 48 weeks

07

Results

Posted Nov 1, 2021

Participant flow

Participant flow — Overall Study
MilestoneEfinaconazole
Started62
Completed50
Not completed12

Outcome measures

PrimaryPercentage of Participants With at Least One Adverse Event
Time frame:
48 weeks
Reported as:
Count of participants · Participants
Percentage of Participants With at Least One Adverse Event
ParticipantsEfinaconazole
Percentage of Participants With at Least One Adverse Event39

Adverse events

Collected over 48 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Efinaconazole0/60 (0%)2/60 (3.3%)20/60 (33.3%)
Most frequent serious events
Most frequent serious events
EventEfinaconazole
PneumoniaInfections and infestations1/60
Ankle fractureInjury, poisoning and procedural complications1/60
Most frequent other events
Most frequent other events
EventEfinaconazole
NasopharyngitisInfections and infestations18/60
HeadacheNervous system disorders6/60
InfluenzaInfections and infestations5/60
ContusionInjury, poisoning and procedural complications4/60
Nail injuryInjury, poisoning and procedural complications4/60
Ingrowing nailSkin and subcutaneous tissue disorders4/60
Tinea pedisInfections and infestations4/60
Food poisoningGastrointestinal disorders3/60

Baseline characteristics

Of the 62 participants who were enrolled in the study, 2 did not apply study drug and were excluded from all analysis populations.

Age, Continuous
Age, Continuous(years)Efinaconazole
Mean13.4 ± 2.29
Sex: Female, Male
Sex: Female, Male(Participants)Efinaconazole
Female20
Male40
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Efinaconazole
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American6
White53
More than one race0
Unknown or Not Reported1
Target Great Tonail
Target Great Tonail(Participants)Efinaconazole
Left32
Right28
08

Study locations

10 sites
  • Valeant Site 01
    Birmingham, Alabama 35201, United States
  • Valeant Site 04
    Fountain Valley, California 92708, United States
  • Valeant Site 03
    Santa Rosa, California 95403, United States
  • Valeant SIte 05
    South Miami, Florida 33143, United States
  • Valeant Site 09
    New Orleans, Louisiana 70130, United States
  • Valeant Site 08
    Baltimore, Maryland 21214, United States
  • Valeant Site 02
    Forest Hills, New York 11375, United States
  • Valeant Site 06
    Philadelphia, Pennsylvania 19107, United States
  • Valeant Site 07
    McAllen, Texas 78501, United States
  • Valeant Site 10
    Santo Domingo, Dominican Republic
09

References and documents

Study documents

  • Protocol and statistical analysis plan · May 10, 2016

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02812771
Lead sponsor
Bausch Health Americas, Inc.
Responsible party
Sponsor
First posted
Jun 24, 2016
Start date
Aug 4, 2016
Primary completion
Jan 14, 2019
Completion
Jan 14, 2019
Results posted
Nov 1, 2021
Last update
Nov 1, 2021

Study contacts

Binu Alexander, MD
study director · Valeant Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion